Exploring the Relationship of Transdiagnostic Mood and Psychosis Symptom Domains with Motor Dysfunction

Jerillyn S. Kent^a Seth G. Disner^{a, b} Abraham C. Van Voorhis^c
Snežana Urošević^{a, b} Michael P. Caligiuri^d Scott R. Sponheim^{a, b, e}

^aDepartment of Psychiatry, University of Minnesota, Minneapolis, MN, USA; ^bMinneapolis VA Health Care System, Minneapolis, MN, USA; ^cThe Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; ^dDepartment of Psychiatry, University of California San Diego, San Diego, CA, USA; ^eDepartment of Psychology, University of Minnesota, Minneapolis, MN, USA

Keywords

Psychomotor slowing · Dyskinesia · Lateralized readiness potential · Psychosis · Bipolar disorder

Abstract

Background: A number of motor abnormalities have been reported in psychotic disorders, including dyskinesia and psychomotor slowing. There is also evidence for many of the same motor abnormalities in biological first-degree relatives and accruing evidence for motor abnormalities in bipolar disorder. In addition to motor dysfunction, there are also shared symptom domains amongst these populations. **Objectives:** We explored the associations of (1) current and lifetime psychosis and mood symptom domains and (2) domains of psychosis proneness with various domains of motor function in a transdiagnostic sample ($n = 149$). **Method:** Individuals with schizophrenia, schizoaffective disorder, or bipolar disorder, biological first-degree relatives of individuals with a psychotic disorder, and controls completed measures of psychomotor speed and movement fluidity, and neural activity related to motor preparation (stimulus-locked lateralized readiness potential, S-LRP) and execution (response-locked LRP) was assessed using EEG. All participants

completed the Brief Psychiatric Rating Scale; patients were additionally assessed for lifetime psychosis and mood episode symptoms, and relatives and controls completed the Chapman psychosis proneness scales. **Results:** Multiple regression revealed levels of current negative symptoms and mania were significantly positively associated with psychomotor slowing even after accounting for current antipsychotic medication dosage and duration of illness. S-LRP onset latency was significantly positively associated with magical ideation. **Conclusion:** Domains of motor function are associated with various mood and psychosis symptom domains in a transdiagnostic sample, which may provide insight into brain abnormalities relevant to the expression of symptoms across disorders.

© 2019 S. Karger AG, Basel

Introduction

Empirical evidence of motor abnormalities in the psychosis spectrum has steadily accrued over the past few decades. The term “motor abnormalities” is intentionally broad, reflecting the diverse array of disturbances and dysfunction that have been reported in this population.

These motor abnormalities range from involuntary movements (i.e., spontaneous dyskinesia [1, 2]), to disturbances in the execution of voluntary movement (e.g., disruptions in motor coordination and sequencing [3], slowness of movement [4]), and also include spontaneous Parkinsonism [1, 2] and the heterogeneous syndrome catatonia [5] (see Walther and Strik [6] and van Harten et al. [7] for reviews). It is important to note that all voluntary motor actions involve varying degrees of non-motor processes; therefore, “psychomotor abnormalities” is a more accurate descriptor for most of the motor abnormalities outlined above (see Morrens et al. [4] for discussion). The identification of motor abnormalities in the psychosis spectrum has highlighted specific brain regions that may be relevant to the pathophysiology of the disorder (e.g., cerebellar dysfunction [8]), and dyskinesia appears to have prognostic value for the development of a psychotic disorder [9, 10].

Motor function has also been studied in biological first-degree relatives of individuals with schizophrenia, who carry genetic liability for the disorder. Abnormalities in a number of domains of motor behavior have been reported in this population, suggesting that motor abnormalities may be an endophenotype reflecting genetic contributions to psychosis. For example, meta-analyses have indicated the presence of motor abnormalities in first-degree relatives that include spontaneous dyskinesia [2] (see also Koning et al. [11], but see Kent et al. [12]), spontaneous Parkinsonism [2] (see also Koning et al. [11] and Kamis et al. [13]), and neurological soft signs [14, 15]. Also, meta-analyses of cognitive and neuropsychological function have revealed psychomotor slowing in first-degree relatives [16, 17].

Outside of the psychomotor disturbances characteristic of mood states (i.e., psychomotor retardation and agitation; increased and decreased activity levels [18, 19]), relatively little attention has been paid to motor function in bipolar disorder. While there is less work examining motor function in bipolar disorder than first-degree relatives of individuals with schizophrenia, there are data to suggest that similar motor abnormalities exist in this population, although the extent to which each motor domain has been studied varies considerably. For example, a meta-analysis of euthymic individuals with bipolar disorder revealed psychomotor slowing in this population, though medication confounds complicated the interpretation of these results [20] (see also Correa-Ghisays et al. [21]). Neurological soft signs have been reported in bipolar disorder (see Hirjak et al. [22] and Peralta and Cuesta [23] for reviews), including in currently psychotic individuals

[24, 25], individuals with no history of psychosis [26], and euthymic individuals [27]. Bolbecker et al. [28] reported balance impairments in euthymic individuals with bipolar disorder during a static task, while Kang et al. [29] reported impaired balance in depressed but not euthymic individuals with bipolar disorder during a dynamic task. Dyskinesia has also been reported in bipolar disorder [30, 31], including one study of euthymic individuals [32], as has Parkinsonism [30].

Findings of motor abnormalities in bipolar disorder are especially interesting when various similarities between bipolar disorder and schizophrenia are considered. Bipolar disorder and schizophrenia have been shown to share genetic risk factors [33]. In addition, there is substantial symptom overlap between psychotic and bipolar disorders. This is most apparent in schizoaffective disorder, wherein both mood and psychotic symptoms are prominent features, and the psychotic features that can be present during mood episodes in bipolar disorder. However, both mood symptoms and episodes also occur in schizophrenia [18], and the status of schizoaffective disorder as a distinct nosological entity has been called into question (see for example Peralta and Cuesta [34]). Given that symptom domains and motor abnormalities are shared by psychotic disorders and bipolar disorder, it would be informative to understand whether specific symptom domains are associated with particular motor abnormalities in a transdiagnostic sample. A relationship between a specific motor abnormality and transdiagnostic clinical phenotype could provide insight into the nature of the transdiagnostic occurrence of the motor dysfunction, and may indicate shared neural substrates, which could enhance our understanding of the underlying neural bases of various symptom domains.

A related question arises when considering subthreshold symptom expression in biological first-degree relatives. In addition to carrying genetic liability for psychosis, as a group these individuals display greater schizotypal symptoms than controls that are similar in content, but not in severity, to domains of symptomatology seen in psychosis (see for example Calkins et al. [35]). It is therefore of interest to examine if motor abnormalities in this population are associated with schizophrenia spectrum symptomatology.

The current study aimed to investigate the mapping of different motor abnormalities onto dimensions of psychotic and mood symptomatology. As discussed above, there are many aspects of (psycho)motor functioning that have been investigated in the context of psychosis, and a comprehensive investigation including each type of mo-

tor abnormality that has been studied in psychosis is out of the scope of the current paper. In this study, we examined two aspects of motor behavior (movement fluidity and psychomotor speed) which we hypothesized to be related to specific symptom domains for associations with various psychotic, mood, and subthreshold psychosis symptom dimensions in transdiagnostic samples. We did the same in a more exploratory capacity for EEG measures of neural activity preceding action. Specifically, we examined the relationship of lifetime occurrence of mood and psychotic symptom domains to these motor variables in a sample of individuals with schizophrenia, schizoaffective disorder, or bipolar disorder. We also examined the relationship of four domains of subthreshold psychotic symptomology (magical ideation, perceptual aberrations, social anhedonia, and physical anhedonia) to motor variables in controls and first-degree biological relatives of individuals with a psychotic disorder. Finally, the relationship of these motor variables to current levels of psychotic and mood symptom domains was explored across all participants.

It should be noted that unipolar depression is also associated with various psychomotor abnormalities (e.g., see Sobin and Sackeim [19] and Peralta and Cuesta [23] for reviews; see also Lohr et al. [36]). The associations between depression as a symptom domain and motor variables will be explored in the current study. However, given that the focus of this study is on the schizophrenia/schizoaffective disorder/bipolar disorder spectrum, individuals with unipolar depression are not included as a patient group.

Our hypotheses regarding which symptom domains would be predictive of motor function were grounded in the literature specific to each motor domain investigated. There have been studies demonstrating the association of psychomotor slowing with negative symptoms in schizophrenia (see Morrens et al. [4] for review; see also Norman et al. [37], Docx et al. [38], and Bervoets et al. [39]). It has been hypothesized that psychomotor slowing is one motor component of a “negative syndrome” [38]. In addition, psychomotor slowing is a symptom of depression [18], and an association between depressive symptoms and psychomotor slowing has been reported in schizophrenia ([40]; see Morrens et al. [4] for review). The possibility that psychomotor slowing (and other deficits) could have the same neural and psychological substrates in individuals with psychotic disorders experiencing depression as those in individuals with depression has been suggested [40]. Therefore, we hypothesize that the negative symptoms and depression symptom domains will be associated with psychomotor slowing.

Dyskinesia results from basal ganglia abnormalities [41, 42], and striatal hyperdopaminergia is a possible contributing mechanism [42]. Striatal hyperdopaminergia has been hypothesized to be an important mechanism in the development of psychosis, particularly positive symptoms [43]. Given this possible shared mechanism, we hypothesize that only the positive symptoms of psychosis will be related to dysfluent movement. Importantly, the movement fluidity data reported here represent a secondary analysis of data previously published. In Kent et al. [12], we reported significantly increased movement dysfluency in a group of individuals with both schizophrenia and schizoaffective disorder (compared to both controls and relatives), but no difference in movement fluency between controls and relatives. Given the possible shared mechanism discussed above, it is possible that increased dysfluency would only be expected in non-proband participants experiencing subthreshold “positive” symptoms. We therefore hypothesize that such symptoms (i.e., magical ideation and perceptual aberrations) will be associated with more dysfluent movement in the combined control and relative sample (note: these Chapman scales provide a richer characterization of these symptoms in comparison to the schizotypal personality questionnaire utilized in Kent et al. [12]).

Neural activity preceding action was investigated using the lateralized readiness potential (LRP). The LRP is calculated by subtracting EEG activity recorded from electrodes on opposite sides of the motor strip during a window preceding a response, with activity specific to the contralateral cortex believed to reflect processes related to motor preparation and execution [44, 45]. The LRP can be measured in relation to stimulus presentation or to response execution. The onset latency of the stimulus-locked LRP (S-LRP) reflects the time between stimulus presentation and the activation of motor preparatory processes, while the onset latency of the response-locked LRP (R-LRP) (measured in milliseconds before the response) reflects the time required for response execution once motor preparatory processes have been initiated [46]. Several studies have reported S-LRP onset latency delays in schizophrenia [46–49], while the literature examining R-LRP onset latency in schizophrenia has been mixed [46–50]. Here again, we are conducting a secondary analysis on data that we have previously published [51]. In Van Voorhis et al. [51], we reported significantly later S-LRP onset latency in both (1) individuals with schizophrenia or schizoaffective disorder and (2) individuals with bipolar disorder compared to first-degree relatives of individuals with a psychotic disorder, but not

controls; there were no differences between groups in R-LRP onset latency. We do not have any specific hypotheses regarding which symptoms will be associated with variance in S-LRP onset latency, however given that relatives and controls were not significantly different from each other in Van Voorhis et al. [51], we hypothesize that subthreshold psychotic symptomology will be associated with S-LRP onset latency in these groups (i.e., any attenuated abnormality might only show up in individuals displaying some degree of subthreshold symptoms). Given the mixed findings regarding R-LRP onset latency in the literature, these analyses are considered exploratory.

Materials and Methods

Participants

The sample was composed of 149 individuals from the following groups: 32 individuals with schizophrenia (mean age = 40.31 years, SD = 11.44 years; 22 male), 14 individuals with schizoaffective disorder (10 with bipolar type, 4 with depressive type; mean age = 45.07 years, SD = 10.05 years; 9 male), 17 individuals with bipolar I disorder (mean age = 47.12 years, SD = 11.10 years; 14 male), 43 biological first-degree relatives of individuals with either schizophrenia or schizoaffective disorder (mean age = 45.86 years, SD = 10.96 years; 18 male), and 43 controls (mean age = 45.42 years, SD = 11.56 years; 24 male).

Three individuals in the schizophrenia group also had diagnoses of bipolar disorder not otherwise specified, and 9 individuals had other current or lifetime mood disorder diagnoses ($n = 2$ with major depressive disorder; $n = 7$ with depressive disorder not otherwise specified). Thirteen individuals with bipolar I disorder had a history of psychotic features during a mood state. Current mood states for the individuals with bipolar I disorder at the time of participation in this study were $n = 4$ depressed, $n = 12$ euthymic, and $n = 1$ unknown. All individuals in the patient groups were outpatients, and diagnoses were determined via clinical interview by trained psychodiagnosticians and subsequent review of these materials by doctoral students or doctoral-level staff (see Procedures section below for details).

One relative had a diagnosis of psychotic disorder not otherwise specified, one had a diagnosis of bipolar I disorder (current mood state euthymic, no history of psychotic features), and 12 had lifetime unipolar mood disorder diagnoses ($n = 8$ with major depressive disorder; $n = 2$ with depressive disorder not otherwise specified; $n = 1$ with a mood disorder due to a general medical condition; $n = 1$ with a substance-induced mood disorder). Two relatives (including one who had a unipolar mood disorder diagnosis) had Axis II Cluster A diagnoses ($n = 1$ with schizoid personality disorder; $n = 1$ with paranoid personality disorder).

Control participants had no current or past Axis I mood or psychotic disorders, no Axis II Cluster A personality disorders, and denied a family history of psychotic disorders. No participants had current alcohol or substance abuse or dependence diagnoses, and no participants in the patient groups were taking anti-Parkinsonian medications. In the patient groups, 54 individuals were taking antipsychotic medication ($n = 5$ taking typical antipsychotics);

33 individuals were taking mood stabilizers ($n = 7$ taking Lithium, $n = 24$ taking divalproex sodium, and $n = 7$ taking other mood stabilizers); 27 individuals were taking antidepressants ($n = 10$ taking SSRIs, $n = 1$ taking an MAOI, and $n = 17$ taking other antidepressants); and 8 individuals were taking benzodiazepines. Of the relatives carrying diagnoses described above, 6 were taking antidepressants, and 1 was taking an atypical antipsychotic medication. Chlorpromazine equivalent dosages were computed for individuals with complete antipsychotic medication dosage data [52].

Not all participants completed every motor task and clinical assessment. Table 1 provides the sample for each motor and clinical measure for each diagnostic group, as well as means and standard deviations. As discussed in the introduction, a portion of the data presented in this study is a secondary analysis of previously published data. Specifically, the movement fluidity data from the individuals with schizophrenia or schizoaffective disorder, relatives, and controls were presented in Kent et al. [12]. Movement fluidity data from the participants with bipolar I disorder have not been previously published. The participants with LRP data in this study are subsamples of the schizophrenia/schizoaffective disorder, depressive type, bipolar disorder, relative, and control samples reported in Van Voorhis et al. [51], and reflect participants for whom both LRP and movement fluidity data were available. LRP data from individuals with schizoaffective disorder, bipolar type and an additional 6 relatives have not been previously published.

Procedures

Clinical and Cognitive Assessment

Procedures were approved by institutional review boards from the Minneapolis VA Health Care System and the University of Minnesota. Data collection occurred as a part of a larger study of individuals with a psychotic disorder or bipolar disorder and their biological first-degree relatives (see Docherty and Sponheim [53] for recruitment procedures). After an informed consent process, participants were administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I [54]) and the Brief Psychiatric Rating Scale (BPRS [55]). IQ was estimated using the Vocabulary and Block Design subtests of the Wechsler Adult Intelligence Scale [56]. Diagnoses (or lack thereof) were determined for each participant through review of all clinical research assessments by advanced clinical psychology graduate students or postdoctoral researchers in consultation with clinical psychologists, and a minimum of two such individuals reached consensus on all diagnoses.

The Operational Criteria Checklist for Psychotic and Affective Illness (OPCRIT) [57] was additionally completed for individuals with a psychotic or bipolar disorder. The OPCRIT records information on the lifetime presence and severity of various psychotic and mood episode symptoms. Controls and relatives of individuals with a psychotic disorder additionally completed the Chapman psychosis proneness scales measuring magical ideation [58], perceptual aberrations [59], physical anhedonia [60], and social anhedonia [61].

Assessments of Motor Function

To assess psychomotor speed, participants were administered the Trail Making Test Part A (Trails A) [62], with time (in seconds) serving as the dependent variable.

As stated in the introduction, this study represents a secondary analysis of the movement fluidity data presented in Kent et al. [12], wherein details regarding data collection and processing are out-

Table 1. Sample size, mean, and standard deviation for demographic, cognitive, clinical, and motor measures for each group

	Schizophrenia			Schizoaffective disorder			Bipolar disorder			Relative			Control		
	<i>n</i>	mean	SD	<i>n</i>	mean	SD	<i>n</i>	mean	SD	<i>n</i>	mean	SD	<i>n</i>	mean	SD
<i>BPRS</i>															
Positive symptoms	32	2.48	1.11	14	2.36	0.93	17	1.45	0.77	43	1.17	0.38	42	1.11	0.23
Negative symptoms	32	2.05	1.19	14	1.76	1.09	17	1.57	0.94	43	1.19	0.38	42	1.17	0.36
Disorganization	32	1.85	0.82	14	1.95	0.79	17	1.60	0.49	43	1.29	0.32	42	1.23	0.31
Mania	32	1.39	0.94	14	1.48	0.91	17	1.47	0.70	43	1.17	0.46	42	1.10	0.22
Depression	32	2.01	0.80	14	2.79	1.13	17	2.61	1.23	43	1.71	0.78	42	1.59	0.65
<i>OPCRIT</i>															
Mania	26	1.12	2.36	10	4.75	1.83	10	5.63	1.07						
Reality distortion	26	2.42	1.22	10	2.25	1.14	10	0.86	1.18						
Depression	26	1.75	1.93	10	4.84	0.37	10	3.55	2.19						
Disorganization	26	2.03	1.12	10	2.19	1.43	10	1.43	1.32						
Negative symptoms	26	1.01	0.74	10	1.13	0.67	10	0.62	0.62						
<i>Chapman scales</i>															
Perceptual aberrations										22	2.09	4.97	36	1.17	1.46
Physical anhedonia										22	10.69	5.91	36	9.17	4.72
Magical ideation										22	4.14	4.39	36	2.71	2.81
Social anhedonia										22	9.19	6.74	36	7.18	4.70
Trails A, s	17	29.76	8.48	10	25.70	7.27	10	27.40	6.88	43	22.67	6.03	28	22.57	5.85
Average log(ANJ)	32	1.41	0.24	14	1.45	0.33	12	1.30	0.17	43	1.25	0.22	43	1.24	0.21
R-LRP onset latency, ms	25	-123.28	59.84	12	-108.40	52.83	14	-109.10	54.33	35	-122.99	48.21	37	-121.62	41.27
S-LRP onset latency, ms	23	200.07	53.30	12	206.71	45.60	14	207.87	60.32	34	174.06	38.52	37	178.74	37.57
Age	32	40.31	11.44	14	45.07	10.05	17	47.12	11.10	43	45.86	10.96	43	45.42	11.56
Estimated IQ	30	89.50	11.25	14	100.50	14.06	14	99.64	14.66	43	107.51	13.99	43	106.74	14.07
CPZ, mg	26	538.46	323.21	13	446.15	443.69	16	85.31	184.98	43	0.29	1.91	43	0	0

lined. Briefly, participants completed a handwriting task using a non-inking pen and a Wacom Intuos 3 digitizing tablet (Wacom, Saitama, Japan) connected to a computer. For the task, participants wrote “lleellee” in cursive in 1, 2, and 4 cm size conditions, completing five trials of each condition in random order. Each participant had a minimum of three acceptable trials (trials with too few strokes or that were interrupted were discarded), and the first eight strokes of each trial were subjected to movement fluidity analysis.

MovAlyzeR software (Neuroscript, LLC, Tempe, AZ, USA) was used to sample pen movements and for data processing and analysis. Data processing steps and additional analysis details are described in Caligiuri et al. [63] and Kent et al. [12]. Briefly, average normalized jerk (ANJ) was calculated [64] as an index of movement smoothness [65]. Jerk, the third time derivative, is calculated and normalized for vertical stroke size and duration (resulting in a unit-free value) [64] and averaged across strokes and trials. ANJ, which reflects changes in acceleration during movement, has been used previously to quantify dysfluent movement, or dyskinesia (indicated by higher ANJ values) [12, 63, 64, 66, 67]. Because our previous work demonstrated no main effect or interactions involving the size condition [12], we averaged ANJ across size conditions for the current secondary analysis.

Similarly, we are conducting a secondary analysis of LRP data for the current study. Data were collected as a part of a stop signal task (SST) paradigm, which was used to investigate the neural correlates of motor inhibition [51]. The SST comprised a Go Only condition and a Go/Stop condition. The current secondary analysis only examined data from the Go Only condition, wherein participants responded to an X replacing either the left or the right crosshair in a row of three crosshairs by pushing a button with their corresponding thumb as quickly as possible. In the Go/Stop condition, a stop signal appeared after a variable delay on 20% of trials, requiring participants to inhibit their responses. The SST

had five blocks, each consisting of 20 Go Only trials, followed by 120 Go/Stop trials, and then 20 Go Only trials; there were never any stop trials during the Go Only trials.

Additional task details and full description of EEG data collection, processing, and analysis are provided in Van Voorhis et al. [51]. Briefly, EEG data were collected with either a 64- or 128-channel Ag/AgCl electrode array and a Biosemi ActiveTwo system (1,024 Hz sampling rate, single earlobe reference signal). Data were re-referenced to linked earlobes, filtered (0.5 Hz high-pass filter, 256 Hz low-pass filter), and de-noised via visual inspection and independent component analysis decomposition [68] and removal of noise ICs. Reconstituted de-noised data were average head re-referenced and epoched and averaged to form event-related potentials for various conditions [51].

The current analysis examines S-LRP and R-LRP onset latencies from the Go Only condition. As described in detail in Van Voorhis et al. [51], LRPs were calculated by low-pass filtering (8 Hz), baseline correcting, and then averaging waveforms for electrodes C3 and C4 for both left and right hand responses. Next, subtraction waveforms were computed to reflect LRP activity corresponding to both left and right hand responses and then averaged. See Van Voorhis et al. [51] for details regarding LRP onset latency calculations, as well as criteria for inclusion of LRP data for each participant.

Statistical Analysis

As an index of current psychotic and mood symptom severity, we averaged BPRS item ratings corresponding to each of the five factors identified by Wilson and Sponheim [69] (positive symptoms, negative symptoms, disorganization, mania symptoms, and depression/anxiety symptoms). As an index of lifetime psychotic and mood symptom expression, we multiplied binary (i.e., symptom coded as present or not present) OPCRIT items by their respective factor loadings [70], which were then summed according

Table 2. Number of participants from each group who have both a given motor and clinical measure

	Schizophrenia	Schizoaffective disorder	Bipolar disorder	Relative	Control
BPRS-Trails A	17	10	10	42	26
OPCRIT-Trails A	12	6	6		
Chapman-Trails A				21	21
BPRS-ANJ	32	14	12	43	42
OPCRIT-ANJ	26	10	7		
Chapman-ANJ				22	36
BPRS-R-LRP	25	12	14	35	36
OPCRIT-R-LRP	19	10	8		
Chapman-R-LRP				17	32
BPRS-S-LRP	23	12	14	34	36
OPCRIT-S-LRP	17	10	8		
Chapman-S-LRP				16	32

to the five factors identified by Dikeos et al. [70] (mania, reality distortion, depression, disorganization, and negative symptoms). Total number of pathological items endorsed was summed for each of the four Chapman scales.

Multiple regression models were used to investigate the association between the domains of each of the three symptom measures (BPRS, OPCRIT, and Chapman Scales) and each of the motor indices (Trails A, ANJ, and LRP). There was a significant pairwise correlation observed between R-LRP and S-LRP onset latency ($r = 0.42$, $p < 0.001$), prompting the use of multivariate multiple regression with two dependent variables (S-LRP onset latency, R-LRP onset latency) for all models predicting LRP onset latency. In all models, age and sex were included as covariates due to their observed association with the outcome variables (age associated with S-LRP ($p < 0.001$) and Trails A ($p = 0.019$); sex associated with ANJ ($p = 0.001$) and S-LRP ($p = 0.005$)). Number of errors was included as a covariate for all models predicting Trails A completion time. Each model included only participants who completed both of the relevant measures; the number of participants from each group included in each model is listed in Table 2.

For models involving the patient groups that yielded significant effects, we conducted follow-up analyses to explore and account for possible effects of antipsychotic medication and duration of illness on the variables of interest. Specifically, models were re-run including only patients for whom complete antipsychotic medication dosage data were available, and then these new models were run again including chlorpromazine equivalent dosages and duration of illness as covariates.

Results

The model investigating the relationship between current symptom severity, measured using the BPRS, and Trails A performance yielded several significant associa-

tions (Fig. 1). Time to complete Trails A was significantly associated with positive symptoms ($\beta = 0.22$, $t = 2.09$, $p = 0.040$), mania ($\beta = 0.20$, $t = 2.02$, $p = 0.047$), and negative symptoms ($\beta = 0.24$, $t = 2.33$, $p = 0.022$) (full model statistics: $F(8, 96) = 4.44$, $p = 0.0001$, adjusted $R^2 = 0.21$). All associations were in the positive direction, meaning that increased symptoms were associated with increased time to complete Trails A. There was no significant association between BPRS factor severity and ANJ (all p values > 0.1). There was no significant association between BPRS factor severity and either of the LRP indices (all p values > 0.1).

Amongst the lifetime symptom factors in patients, measured using the OPCRIT, there was a trend-level association between reality distortion (delusions and hallucinations) and Trails A completion time ($\beta = 0.45$, $t = 1.87$, $p = 0.081$) (full model statistics: $F(8, 15) = 1.14$, $p = 0.3952$, adjusted $R^2 = 0.05$). The direction of this association indicates that greater lifetime reality distortion symptoms were associated with longer Trails A completion time. However, this result stems from a markedly smaller sample than the previously reported BPRS findings ($n = 24$, vs. $n = 105$ in the BPRS analysis). Reality distortion showed a significant association with S-LRP onset latency ($\beta = -0.37$, $t = -2.36$, $p = 0.026$) (full model statistics for S-LRP: $F(7, 27) = 3.27$, $p = 0.012$, adjusted $R^2 = 0.32$). The negative association in this reality distortion finding suggests that these symptoms were related to faster S-LRP onset latency when accounting for all other OPCRIT symptom factors; however, it is important to note that the sample for this analysis was also

Fig. 1. Associations between BPRS symptom factors and Trails A (* $p < 0.05$).

quite small ($n = 35$). There was no significant association between OPCRIT factors and the other motor indices (all p values > 0.1).

Subthreshold symptom severity, measured using the Chapman scales, was not associated with Trails A or ANJ (all p values > 0.1). However, there was a significant association between the magical ideation score and S-LRP onset latency ($\beta = 0.42$, $t = 2.99$, $p = 0.005$) (full model statistics for S-LRP: $F(6, 41) = 4.22$, $p = 0.002$, adjusted $R^2 = 0.29$) (Fig. 2). The positive direction of this association indicates that greater magical ideation was associated with longer S-LRP onset latency. This analysis did not include the two relatives with psychotic disorder not otherwise specified and bipolar disorder diagnoses due to lack of Chapman data from these participants. β , t , and p values for all models are listed in Table 3.

Follow-Up Analyses

When the BPRS-Trails A model was re-run including only those participants for whom complete antipsychotic medication dosage data were available ($n = 102$, 3 fewer participants), the significant associations between Trails A and negative symptoms ($\beta = 0.28$, $t = 2.54$, $p = 0.013$) and mania ($\beta = 0.24$, $t = 2.28$, $p = 0.025$) persisted, and the association between Trails A and positive symptoms dropped to $\beta = 0.17$, $t = 1.63$, $p = 0.106$ (full model statistics: $F(8, 93) = 3.69$, $p = 0.0009$, adjusted $R^2 = 0.18$). When chlorpromazine equivalent dosage and duration of illness were entered into the model, both negative symptoms ($\beta = 0.30$, $t = 2.71$, $p = 0.008$) and mania ($\beta = 0.21$, $t = 2.02$, $p = 0.046$) were still significantly associated with Trails A (positive symptom association $p = 0.419$). Chlorpromazine equivalent dosage was not significantly associated with Trails A ($p = 0.858$), and there was a trend-level as-

Fig. 2. Associations between the Chapman scales and S-LRP onset latency (* $p < 0.01$).

sociation wherein longer duration of illness was associated with longer Trails A time ($\beta = 0.22$, $t = 1.73$, $p = 0.087$) (full model statistics: $F(10, 91) = 3.35$, $p = 0.0009$, adjusted $R^2 = 0.19$).

When the OPCRIT-S-LRP model was re-run including only those participants for whom complete antipsychotic medication dosage data were available ($n = 30$, 5 fewer participants), the significant association between reality distortion and S-LRP onset latency persisted ($\beta = -0.42$, $t = -2.53$, $p = 0.019$) (full model statistics: $F(7, 22) = 3.19$, $p = 0.017$, adjusted $R^2 = 0.35$). When chlorpromazine equivalent dosage and duration of illness were entered into the model, the significant association between reality distortion and S-LRP onset latency persisted ($\beta = -0.42$, $t = -2.44$, $p = 0.024$). Neither chlorpromazine equivalent dosage ($p = 0.615$) nor duration of illness ($p =$

0.623) were significantly associated with S-LRP onset latency (full model statistics: $F(9, 20) = 2.37$, $p = 0.0516$, adjusted $R^2 = 0.30$).

In order to further examine the counterintuitive positive association between mania and Trails A, we conducted an exploratory analysis wherein status regarding taking divalproex sodium, a mood stabilizer with possible parkinsonian motor side effects [71], was included as a binary (i.e., taking or not taking divalproex sodium) covariate in the model already including chlorpromazine equivalent dosage and duration of illness as covariates. In this model, negative symptoms ($\beta = 0.26$, $t = 2.30$, $p = 0.024$) were still significantly associated with Trails A, and the association between mania and Trails A dropped to the trend level ($\beta = 0.18$, $t = 1.79$, $p = 0.076$). Neither chlorpromazine equivalent dosage ($p = 0.844$) nor dura-

Table 3. Statistics for all models

Measure and factor/ symptom	Trails A				ANJ				S-LRP				R-LRP			
	<i>n</i>	β	<i>T</i>	<i>p</i>	<i>n</i>	β	<i>T</i>	<i>p</i>	<i>n</i>	β	<i>T</i>	<i>p</i>	<i>n</i>	β	<i>T</i>	<i>p</i>
<i>BPRS</i>																
Positive symptoms	105	0.215	2.090	0.040 ^b	143	0.127	1.320	0.188	119	0.011	0.110	0.915	122	0.107	0.940	0.350
Negative symptoms	105	0.245	2.330	0.022 ^b	143	0.130	1.490	0.139	119	0.099	1.030	0.303	122	0.014	0.130	0.897
Disorganization	105	0.144	1.190	0.235	143	0.174	1.460	0.148	119	0.067	0.550	0.584	122	-0.051	-0.370	0.709
Mania	105	0.198	2.020	0.047 ^b	143	0.072	0.700	0.487	119	0.058	0.530	0.597	122	-0.034	-0.280	0.782
Depression	105	-0.144	-1.370	0.173	143	-0.028	-0.310	0.760	119	0.116	1.200	0.232	122	0.046	0.430	0.667
<i>OPCRIT</i>																
Mania	24	0.053	0.200	0.846	43	0.121	0.600	0.556	35	0.187	1.160	0.254	37	0.210	1.060	0.296
Reality distortion	24	0.448	1.870	0.081 ^a	43	-0.069	-0.390	0.701	35	-0.373	-2.360	0.026 ^b	37	0.022	0.110	0.912
Depression	24	-0.267	-1.070	0.302	43	-0.059	-0.310	0.757	35	-0.091	-0.570	0.573	37	-0.035	-0.180	0.858
Disorganization	24	-0.206	-0.760	0.459	43	-0.071	-0.400	0.691	35	0.009	0.050	0.960	37	-0.215	-1.060	0.297
Negative symptoms	24	0.186	0.690	0.498	43	0.082	0.470	0.643	35	0.067	0.450	0.657	37	0.156	0.850	0.401
<i>Chapman scales</i>																
Perceptual aberrations	42	0.262	1.360	0.182	58	0.163	1.050	0.300	48	0.004	0.020	0.981	49	-0.018	-0.100	0.917
Physical anhedonia	42	0.062	0.260	0.794	58	-0.003	-0.020	0.987	48	0.071	0.420	0.678	49	-0.014	-0.070	0.947
Magical ideation	42	-0.015	-0.090	0.932	58	0.050	0.330	0.744	48	0.419	2.990	0.005 ^c	49	0.208	1.240	0.222
Social anhedonia	42	0.042	0.170	0.867	58	-0.161	-0.830	0.408	48	-0.108	-0.590	0.559	49	0.059	0.280	0.780

^a $p < 0.1$; ^b $p < 0.05$; ^c $p < 0.01$.

tion of illness ($p = 0.422$) were significantly associated with Trails A in this model, but there was a trend-level association wherein taking divalproex sodium was associated with longer Trails A time ($\beta = 0.22$, $t = 1.86$, $p = 0.066$) (full model statistics: $F(11, 90) = 3.45$, $p = 0.0005$, adjusted $R^2 = 0.21$).

Discussion

Our examination of the association of deviations in motor function with symptomatology across psychotic and bipolar disorders revealed that multiple domains of current symptom severity are associated with psychomotor slowing. When current antipsychotic medication dosage and duration of illness were included in the model, the relationships of negative symptoms and mania with psychomotor slowing are robust. While the association between negative symptoms and slower psychomotor activity is consistent with hypotheses and previous research (see Introduction), the finding of increased mania being associated with slower psychomotor activity is unexpected given the psychomotor features characteristic of mania. While exploratory post hoc medication analysis suggested that this relationship could be partially accounted for by mood stabilizing medication (though see below in the discussion for important caveats), the persistence of this relationship at the trend level is notable. Like all psychomotor tasks [4], Trails A involves non-motor processes. While speculative, it is possible that the association between Trails A completion time and mania severity reflects the impact of mania symptoms on the non-motor

processes recruited (e.g., attention, goal directedness) by this task. It is important to note that variability in completion time associated with Trails A errors was accounted for in the models.

The finding of an association between magical ideation and S-LRP onset latency was broadly consistent with our hypothesis, indicating that S-LRP onset latencies more similar to those seen in psychosis are associated with more subthreshold psychosis symptoms. This finding compliments existing literature showing delayed S-LRP onset latency in individuals with psychosis [46–49], and suggests that S-LRP onset latency abnormalities in non-psychotic individuals are associated with intermediate symptom expression rather than genetic liability per se [51]. Longer S-LRP onset latency is reflective of delayed response selection and initiation of response preparation. However, to better understand what this abnormality associated with schizophrenia spectrum symptoms reflects, these findings must be considered in the context of the task. In a similar task, Kappenman et al. [46] demonstrated that task-relevant (i.e., responding as quickly and accurately as possible) higher-order processes affecting response selection and motor preparation explained S-LRP onset delays in individuals with schizophrenia. In addition, fMRI studies of speeded responding have implicated the basal ganglia, pre-SMA (supplementary motor area), and frontal areas [72–74].

It is difficult to know how to interpret the relationship between lifetime reality distortion symptoms and S-LRP onset latency in patients, as this relationship is in the opposite direction as that in controls and relatives. The smaller sample size for this analysis may be an important

factor, and future work examining the relationship of motor function to indices of lifetime symptoms should include larger samples.

There are several limitations of the current study that must be addressed. First, antipsychotic medications have known motor side effects, and the fact that the majority of the patients in this study were taking antipsychotic medication poses a major confound for the study of motor function. We have attempted to account for effects related to current antipsychotic medication dosage and approximate duration of antipsychotic treatment by re-running all models with significant effects with chlorpromazine equivalent dosages and duration of illness included. However, motor side effects of antipsychotic medication are certainly related to more than simply current dosage, and while we have attempted to account for duration of treatment with antipsychotics by including duration of illness as a covariate as well, this is a very rough proxy and of course reflects additional factors. Furthermore, there is also the issue of shared variance between such covariates and diagnosis/symptoms, with this also being a serious concern for the exploratory analysis including on versus off divalproex sodium, making it difficult to draw firm conclusions regarding variance accounted for by medication. In summary, we have attempted to understand the effects that some medications may be having on our dependent variables, but this study is not designed to interrogate these questions.

In addition to the possibility of motor side effects, psychotropic medications impact symptoms as well, and therefore future research should study the relationship between symptom domains and motor function in medication-naïve samples. An additional limitation of this study relates to sample size. Because not all measures were administered to all participants, some models had smaller sample sizes than others, with the model examining the relationship of lifetime symptomology to psychomotor slowing in patients particularly underpowered, as previously noted.

A final limitation concerns the scope of the current study and of the particular motor measures used. Indeed, we have only been able to begin interrogating the broader question of the relationships between transdiagnostic motor dysfunction and clinical phenomenology. This is reflected in both the fact that we only included measures of three aspects of motor function, and in the limitations inherent to the specific measures we used. For example, Trails A assesses both motor speed and visual search [75], and it is therefore possible that the relationship between Trails A performance and symptoms reflects the relation-

ship between visual search ability and symptoms to some degree. Importantly, while visual search ability could be considered a confound in the context of the current study given the nature of the Trails A task, it is essential to remember that all psychomotor functioning involves a variety of motor (e.g., speed, coordination) and non-motor processes (e.g., visuospatial monitoring, higher-order processes) [4]. Attempts to separate motor and non-motor processes are futile and given that non-motor processes are indeed essential to motor behavior [4], any such attempts, even if possible, would be of limited utility. In addition, as we have previously discussed [12], handwriting fluency is a less demanding neuromuscular control task than force stability maintenance; it is therefore possible that a different measure of dyskinesia could have been more sensitive to more subtle levels of dyskinesia. Finally, as discussed above, task parameters have been shown to affect group differences in S-LRP onset latency [46], thereby circumscribing the generalizability of our findings.

In conclusion, the results of the present study demonstrate the relationship between psychotic and mood symptom domains and domains of motor dysfunction in a transdiagnostic sample. Both mania and negative symptoms were associated with psychomotor slowing. In addition, a relationship between variability in psychomotor processes and subthreshold symptomology was demonstrated for S-LRP onset latency, which was related to magical ideation. It is possible that the pattern regarding which symptom domains are associated with various motor indices may highlight particular neural substrates as being potentially relevant for the expression of certain symptoms. Furthermore, investigation of the relationship of transdiagnostic symptom domains with motor function may aid in further identifying motor abnormalities relevant to psychopathology, which dovetails with the recent addition of a sensorimotor domain to the National Institute of Mental Health's Research Domain Criteria framework.

Acknowledgement

We are grateful to Seung Suk Kang and Mallory Skorheim for assistance with EEG and handwriting data analysis, respectively.

Statement of Ethics

All participants gave written informed consent, and the study protocol was approved by the Minneapolis VA Health Care System and the University of Minnesota IRBs. This research was conducted in accordance with the Declaration of Helsinki.

Disclosure Statement

The authors have no conflicts of interest to declare.

Funding Sources

This research was supported by a Merit Review Award #I01CX000227 from the U.S. Department of Veterans Affairs, Clinical Sciences Research and Development Research Program, and award number U01MH108150 from the National Institute of Mental Health to S.R.S. J.S.K. was supported by a Ruth L. Kirschstein National Research Service Award (award number F32MH112334) from the National Institute of Mental Health. The content is sole-

ly the responsibility of the authors and does not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health. These funding sources played no role in preparation of data or the manuscript.

Author Contributions

J.S.K., S.G.D., and S.R.S. conceived of the study. S.R.S. oversaw data collection. S.G.D., J.S.K., A.C.V.V., S.U., M.P.C., and S.R.S. analyzed the data. J.S.K. and S.G.D. drafted the manuscript, S.R.S. provided critical feedback and substantially edited the manuscript, and M.P.C. and S.U. provided critical feedback on the manuscript.

References

- 1 Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naïve patients with first-episode psychoses: a systematic review. *Psychol Med*. 2009 Jul;39(7):1065–76.
- 2 Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naïve patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. *Schizophr Bull*. 2010 Jul;36(4):723–31.
- 3 Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. *Schizophr Bull*. 2005 Oct;31(4):962–77.
- 4 Morrens M, Hulstijn W, Sabbe B. Psychomotor slowing in schizophrenia. *Schizophr Bull*. 2007 Jul;33(4):1038–53.
- 5 Walther S, Strik W. Catatonia. *CNS Spectr*. 2016 Aug;21(4):341–8.
- 6 Walther S, Strik W. Motor symptoms and schizophrenia. *Neuropsychobiology*. 2012; 66(2):77–92.
- 7 van Harten PN, Walther S, Kent JS, Sponheim SR, Mittal VA. The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. *Neurosci Biobehav Rev*. 2017 Sep;80:476–87.
- 8 Andreasen NC, Pierson R. The role of the cerebellum in schizophrenia. *Biol Psychiatry*. 2008 Jul;64(2):81–8.
- 9 Callaway DA, Perkins DO, Woods SW, Liu L, Addington J. Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. *Schizophr Res*. 2014 Nov;159(2-3):263–6.
- 10 Mittal VA, Walker EF. Movement abnormalities predict conversion to Axis I psychosis among prodromal adolescents. *J Abnorm Psychol*. 2007 Nov;116(4):796–803.
- 11 Koning JP, Kahn RS, Tenback DE, van Schelven LJ, van Harten PN. Movement disorders in nonpsychotic siblings of patients with non-affective psychosis. *Psychiatry Res*. 2011 Jun; 188(1):133–7.
- 12 Kent JS, Caligiuri MP, Skorheim MK, Lano TJ, Mittal VA, Sponheim SR. Instrument-based assessment of motor function yields no evidence of dyskinesia in adult first-degree biological relatives of individuals with schizophrenia and schizoaffective disorder. *Psychiatry Res*. 2019 Feb;272:135–40.
- 13 Kamis D, Stratton L, Calvó M, Padilla E, Florenzano N, Guerrero G, et al. Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population. *Schizophr Res*. 2015 May;164(1-3):250–5.
- 14 Chan RC, Xu T, Heinrichs RW, Yu Y, Gong QY. Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2010 May;34(6):889–96.
- 15 Neelam K, Garg D, Marshall M. A systematic review and meta-analysis of neurological soft signs in relatives of people with schizophrenia. *BMC Psychiatry*. 2011 Aug;11(1):139.
- 16 Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. *Schizophr Res*. 2004 Dec;71(2-3):285–95.
- 17 Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. *Schizophr Bull*. 2006 Jan;32(1):179–94.
- 18 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington (VA): American Psychiatric Association; 2013. <https://doi.org/10.1176/appi.books.9780890425596>.
- 19 Sobin C, Sackeim HA. Psychomotor symptoms of depression. *Am J Psychiatry*. 1997 Jan;154(1):4–17.
- 20 Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord*. 2009 Feb;113(1-2):1–20.
- 21 Correa-Ghisays P, Balanzá-Martínez V, Selva-Vera G, Vila-Francis J, Soria-Olivas E, Vivas-Lalinde J, et al. Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study. *J Affect Disord*. 2017 Jun; 215:156–62.
- 22 Hirjak D, Meyer-Lindenberg A, Fritze S, Sambataro F, Kubera KM, Wolf RC. Motor dysfunction as research domain across bipolar, obsessive-compulsive and neurodevelopmental disorders. *Neurosci Biobehav Rev*. 2018 Dec;95:315–35.
- 23 Peralta V, Cuesta MJ. Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through “Functional” (Neuro)Psychiatric Disorders. *Schizophr Bull*. 2017 Sep; 43(5):956–71.
- 24 Whitty P, Clarke M, McTigue O, Browne S, Gervin M, Kamali M, et al. Diagnostic specificity and predictors of neurological soft signs in schizophrenia, bipolar disorder and other psychoses over the first 4 years of illness. *Schizophr Res*. 2006 Sep;86(1-3):110–7.
- 25 Nasrallah HA, Tippin J, McCalley-Whitters M. Neurological soft signs in manic patients. A comparison with Schizophrenic and control groups. *J Affect Disord*. 1983 Feb;5(1):45–50.
- 26 Zhao Q, Ma YT, Lui SS, Liu WH, Xu T, Yu X, et al. Neurological soft signs discriminate schizophrenia from major depression but not bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013 Jun;43:72–8.
- 27 Chrobak AA, Siwek GP, Siuda-Krzywicka K, Arciszewska A, Starowicz-Filip A, Siwek M, et al. Neurological and cerebellar soft signs do not discriminate schizophrenia from bipolar disorder patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016 Jan;64:96–101.
- 28 Bolbecker AR, Hong SL, Kent JS, Klaunig MJ, O'Donnell BF, Hetrick WP. Postural control in bipolar disorder: increased sway area and decreased dynamical complexity. *PLoS One*. 2011;6(5):e19824.
- 29 Kang GE, Mickey BJ, Krembs BS, McInnis MG, Gross MM. The effect of mood phases on balance control in bipolar disorder. *J Biomech*. 2019 Jan;82:266–70.

- 30 Lohr JB, Caligiuri MP. Abnormalities in motor physiology in bipolar disorder. *J Neuro-psychiatry Clin Neurosci*. 2006;18(3):342–9.
- 31 Crespo Y, Ibañez A, Soriano MF, Iglesias S, Aznarte JL. Handwriting movements for assessment of motor symptoms in schizophrenia spectrum disorders and bipolar disorder. *PLoS One*. 2019 Mar;14(3):e0213657.
- 32 Lage GM, Malloy-Diniz LF, Neves FS, Gallo LG, Valentini AS, Corrêa H. A kinematic analysis of manual aiming control on euthymic bipolar disorder. *Psychiatry Res*. 2013 Jul; 208(2):140–4.
- 33 Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al.; International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009 Aug;460(7256):748–52.
- 34 Peralta V, Cuesta MJ. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. *J Affect Disord*. 2008 May;108(1-2):71–86.
- 35 Calkins ME, Curtis CE, Grove WM, Iacono WG. Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients. *Schizophr Bull*. 2004;30(2):317–25.
- 36 Lohr JB, May T, Caligiuri MP. Quantitative assessment of motor abnormalities in untreated patients with major depressive disorder. *J Affect Disord*. 2013 Mar;146(1):84–90.
- 37 Norman RM, Malla AK, Cortese L, Diaz F. Aspects of dysphoria and symptoms of schizophrenia. *Psychol Med*. 1998 Nov;28(6): 1433–41.
- 38 Docx L, Morrens M, Bervoets C, Hulstijn W, Fransen E, De Hert M, et al. Parsing the components of the psychomotor syndrome in schizophrenia. *Acta Psychiatr Scand*. 2012 Oct;126(4):256–65.
- 39 Bervoets C, Docx L, Sabbe B, Vermeylen S, Van Den Bossche MJ, Morsel A, et al. The nature of the relationship of psychomotor slowing with negative symptomatology in schizophrenia. *Cogn Neuropsychiatry*. 2014;19(1):36–46.
- 40 Holthausen EA, Wiersma D, Knegtering RH, Van den Bosch RJ. Psychopathology and cognition in schizophrenia spectrum disorders: the role of depressive symptoms. *Schizophr Res*. 1999 Aug;39(1):65–71.
- 41 Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ. The expanding universe of disorders of the basal ganglia. *Lancet*. 2014 Aug;384(9942):523–31.
- 42 Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “pre-frontal” and “limbic” functions. *Prog Brain Res*. 1990;85:119–46.
- 43 Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. *Schizophr Bull*. 2009 May; 35(3):549–62.
- 44 Coles MG. Modern mind-brain reading: psychophysiology, physiology, and cognition. *Psychophysiology*. 1989 May;26(3):251–69.
- 45 Smulders FT, Miller JO. The Lateralized Readiness Potential. In: Kappenman ES, Luck SJ, editors. *The Oxford Handbook of Event-Related Potential Components*. New York (NY): Oxford University Press; 2011. <https://doi.org/10.1093/oxfordhob/9780195374148.013.0115>.
- 46 Kappenman ES, Luck SJ, Kring AM, Lesh TA, Mangun GR, Niendam T, et al. Electrophysiological Evidence for Impaired Control of Motor Output in Schizophrenia. *Cereb Cortex*. 2016;26:1891–1899.
- 47 Kappenman ES, Kaiser ST, Robinson BM, Morris SE, Hahn B, Beck VM, et al. Response activation impairments in schizophrenia: evidence from the lateralized readiness potential. *Psychophysiology*. 2012 Jan;49(1):73–84.
- 48 Karayanidis F, Nicholson R, Schall U, Meem L, Fulham R, Michie PT. Switching between univalent task-sets in schizophrenia: ERP evidence of an anticipatory task-set reconfiguration deficit. *Clin Neurophysiol*. 2006 Oct;117(10):2172–90.
- 49 Luck SJ, Kappenman ES, Fuller RL, Robinson B, Summerfelt A, Gold JM. Impaired response selection in schizophrenia: evidence from the P3 wave and the lateralized readiness potential. *Psychophysiology*. 2009 Jul;46(4):776–86.
- 50 Kieffaber PD, O'Donnell BF, Shekhar A, Hetrick WP. Event related brain potential evidence for preserved attentional set switching in schizophrenia. *Schizophr Res*. 2007 Jul; 93(1-3):355–65.
- 51 Van Voorhis AC, Kent JS, Kang SS, Goghari VM, MacDonald AW 3rd, Sponheim SR. Abnormal neural functions associated with motor inhibition deficits in schizophrenia and bipolar disorder. *Hum Brain Mapp*. 2019 Dec; 40(18):5397–411.
- 52 Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. *Biol Psychiatry*. 2010 Feb;67(3):255–62.
- 53 Docherty AR, Sponheim SR. Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. *J Abnorm Psychol*. 2008 Nov;117(4):788–98.
- 54 First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Arlington: American Psychiatric Publishing Incorporated; 1997.
- 55 Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MF, Shaner A. Manual for the Expanded Brief Psychiatric Rating Scale. *Int J Methods Psychiatr Res*. 1993;3:227–44.
- 56 Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale (3rd ed.) Administration and Scoring Manual. San Antonio: Psychological Corporation/Harcourt Brace; 1997.
- 57 McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. *Arch Gen Psychiatry*. 1991 Aug;48(8):764–70.
- 58 Eckblad M, Chapman LJ. Magical ideation as an indicator of schizotypy. *J Consult Clin Psychol*. 1983 Apr;51(2):215–25.
- 59 Chapman LJ, Chapman JP, Raulin ML. Body-image aberration in Schizophrenia. *J Abnorm Psychol*. 1978 Aug;87(4):399–407.
- 60 Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. *J Abnorm Psychol*. 1976 Aug;85(4):374–82.
- 61 Mishlove M, Chapman LJ. Social anhedonia in the prediction of psychosis proneness. *J Abnorm Psychol*. 1985 Aug;94(3):384–96.
- 62 Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. 2nd ed. Tucson: Neuropsychology Press; 1993.
- 63 Caligiuri MP, Teulings HL, Dean CE, Lohr JB. A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. *J Clin Psychopharmacol*. 2015 Apr;35(2):168–74.
- 64 Teulings HL, Contreras-Vidal JL, Stelmach GE, Adler CH. Parkinsonism reduces coordination of fingers, wrist, and arm in fine motor control. *Exp Neurol*. 1997 Jul;146(1):159–70.
- 65 Hogan N, Flash T. Moving gracefully: quantitative theories of motor coordination. *Trends Neurosci*. 1987;10(4):170–4.
- 66 Caligiuri MP, Teulings HL, Dean CE, Niculescu AB 3rd, Lohr JB. Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics. *Psychiatry Res*. 2010 May; 177(1-2):77–83.
- 67 Dean DJ, Teulings HL, Caligiuri M, Mittal VA. Handwriting analysis indicates spontaneous dyskinesias in neuroleptic naïve adolescents at high risk for psychosis. *J Vis Exp*. 2013 Nov;(81):e50852.
- 68 Hyvärinen A, Oja E. Independent component analysis: algorithms and applications. *Neural Netw*. 2000 May-Jun;13(4-5):411–30.
- 69 Wilson S, Sponheim SR. Dimensions underlying psychotic and manic symptomatology: extending normal-range personality traits to schizophrenia and bipolar spectra. *Compr Psychiatry*. 2014 Nov;55(8):1809–19.
- 70 Dikeos DG, Wickham H, McDonald C, Walshe M, Sigmundsson T, Bramon E, et al. Distribution of symptom dimensions across Kraepelinian divisions. *Br J Psychiatry*. 2006 Oct;189(4):346–53.
- 71 Brugger F, Bhatia KP, Besag FM. Valproate-Associated Parkinsonism: A Critical Review of the Literature. *CNS Drugs*. 2016 Jun;30(6):527–40.
- 72 Forstmann BU, Dutilh G, Brown S, Neumann J, von Cramon DY, Ridderinkhof KR, et al. Striatum and pre-SMA facilitate decision-making under time pressure. *Proc Natl Acad Sci USA*. 2008 Nov;105(45):17538–42.
- 73 van Veen V, Krug MK, Carter CS. The neural and computational basis of controlled speed-accuracy tradeoff during task performance. *J Cogn Neurosci*. 2008 Nov;20(11):1952–65.
- 74 Ivanoff J, Branning P, Marois R. fMRI evidence for a dual process account of the speed-accuracy tradeoff in decision-making. *PLoS One*. 2008 Jul;3(7):e2635.
- 75 Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. *Nat Protoc*. 2006;1(5):2277–81.